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CD19 as a Membrane-Anchored Adaptor Protein
of B Lymphocytes: Costimulation of Lipid
and Protein Kinases by Recruitment of Vav
CD21 (Dempsey et al., 1996). CD19 also promotes the
development and maintenance of the B-1 subset of B
lymphocytes (Engel et al., 1995; Rickert et al., 1995;
Krop et al., 1996), which expresses a distinct V gene
repertoire, and it may regulate the expression of the
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on [Ca21]i is associated with the enhanced generationLondon NW7 1AA
of inositol 1,4,5-trisphosphate [I(1,4,5)P3]; ligating CD19United Kingdom
alone also generates I(1,4,5)P3, although the amounts
are less. The mechanism for this function of CD19 is not
known, but both the synergistic and the direct effectsSummary
of CD19 on the production of I(1,4,5)P3 occur without
its altering the tyrosine phosphorylation of phospholi-CD19 is a coreceptor that amplifies signaling by mem-
pase C (PLC)±g (Carter et al., 1991), suggesting thatbrane immunoglobulin (mIg) to promote responses of
CD19 either enhances the efficiency of PLCg or in-the B lymphocyte to T-dependent antigens. Vav is a
creases the availability of the substrate, phosphatidyl-guanine nucleotide exchange factor for the Rho, Rac,
inositol 4,5-bisphosphate [PI(4,5)P2],which may becomeCdc42 family of small GTPases. We found that coligat-
rate limiting for inositol lipid hydrolysis (Stephens et al.,ing mIg and CD19 causes a synergistic increase in
1993), or does both.the tyrosine phosphorylation of CD19. Phosphorylated
CD19 also costimulates with mIg the mitogen-acti-tyrosine-391 of CD19 binds Vav to mediate a sustained
vated protein (MAP) kinases ERK2 (extracellular signal±increase in intracellular Ca21 concentration. This re-
regulated protein kinase 2), JNK/SAPK (c-Jun N-terminalsponse correlates with activation by the CD19±Vav
kinase/stress-activated protein kinase), and p38 (Li etcomplex ofphosphatidylinositol 4-phosphate 5-kinase
al., 1997; Tooze et al., 1997). Although ligating mIg orfor the synthesis of phosphatidylinositol 4,5-bisphos-
CD19 alone causes modest or no activation of thesephate. Interaction of CD19 with Vav also mediates the
kinases, their coligation causes robust activation of allsynergistic activation of the mitogen-activated protein
three, even at low levels of mIg cross-linking. Therefore,kinase JNK. Therefore, CD19 is a membrane adaptor
at least two general pathways of signaling by mIg areprotein that recruits Vav for the activation of lipid and
up-regulated by CD19: phosphatidylinositol metabo-protein kinases.
lism, leading to elevated [Ca21]i, and the MAP kinase
cascades.
Vav and the Rho family of small guanosine triphospha-Introduction
tases (GTPases) offer a means by which these two ap-
parently unrelated pathways may be stimulated in syn-CD19 is an essential coreceptor for membrane immuno-
chrony. Both Rho and Rac have been shown to interactglobulin (mIg), the antigen receptor of B lymphocytes. It
with phosphatidylinositol 4-phosphate 5-kinase (PIP5K)is required for the formation of germinal centers and the
(Chong et al., 1994; Hartwig et al., 1995; Tolias et al.,normal production of antibody in response to T-dependent
1995; Ren et al., 1996), which synthesizes PI(4,5)P2 fromantigens; its deletion impairs and its overexpression
phosphatidylinositol 4-phosphate (PI4P), and Rac initi-augments these responses (Engel et al., 1995; Rickert
ates a MAP kinase pathway leading to JNK (Crespo etet al., 1995; Sato et al., 1995). Through its association
al., 1996). The activation of Rho and Rac requires theirwith the complement receptor, CD21, CD19 also links
loading with guanosine triphosphate (GTP), and Vav isactivation of the B lymphocyte to innate immune recog-
a guanine nucleotide exchange factor (GEF) for this fam-nition of antigen. The potential of the CD19±CD21 com-
ily of GTPases that is expressed relatively exclusivelyplex for positively regulating immune responses is ex-
in hematopoietic cells (Katzav et al., 1989; Crespo etemplified by the large increment in immunogenicity
al., 1997). This function of Vav is mediated by its Dblachieved by tagging antigen with C3d, the ligand for
homology domain and is positively regulated in vitro by
tyrosine phosphorylation (Crespo et al., 1997; Han et al.,
1997). In B and T lymphocytes, Vav is phosphorylated§Present address: The Babraham Institute, Babraham, Cambridge
following ligation of the antigen receptors (Bustelo andCB2 4AT, United Kingdom.
Barbacid, 1992; Bustelo et al., 1992; Margolis et al.,‖ To whom correspondence should be addressed (e-mail: dtf1000@
cus.cam.ac.uk). 1992). In addition, Vav is the only GEF that contains a
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Src homology (SH)±2 domain, suggesting that its func-
tion may also be regulated by interaction with proteins
that have become tyrosine phosphorylated. Consistent
with this possibility is the finding that in T lymphocytes,
Vav-dependent functions are enhanced by coexpres-
sion of SLP-76, which, when tyrosine phosphorylated,
serves as an adaptor for Vav (Reif et al., 1994; Wu et
al., 1996; Raab et al., 1997).
Several observations have suggested that CD19 may
recruit Vav to amplify B lymphocyte activation. CD19 is
tyrosine phosphorylated when either it or mIg is ligated
(Tuveson et al., 1993), and tyrosine-phosphorylated
CD19 associates with Vav (Weng et al., 1994). Ligating
CD19 alone induces tyrosine phosphorylation of Vav
(Weng et al., 1994; Sato et al., 1997), and coligating
CD19 with mIg causes synergistic phosphorylation of
this GEF (Li et al., 1997). CD19 recruits phosphatidylino-
sitol 3-kinase (PI3K), the product of which has been
shown recently to promote the activation of Vav (Han
et al., 1998). Mice lacking Vav (Tarakhovsky et al., 1995;
Zhang et al., 1995) share with CD192/2 mice (Engel et
al., 1995; Rickert et al., 1995) diminished numbers of
B-1 cells. Accordingly, we have examined whether the
interaction of CD19 with Vav mediates its role as a mem-
brane-anchored adaptor protein that amplifies mIg sig-
naling.
Results
Phosphorylating Tyrosine-391 of CD19
Figure 1. Enhancement of Vav Association with CD19 by ColigatingMediates Binding of Vav CD19 to mIg
Ligating CD19 has been shown to induce an association
Splenic B cells were preincubated with the following biotinylated
with Vav (Weng et al., 1994), but the basis for the interac- antibody fragments: control Fab (10 mg/ml), Fab anti-CD19 (10 mg/
tion isnot known. We performed two sets of experiments ml), Fab anti-k (5 mg/ml), or Fab anti-k and Fab anti-CD19 together.
The cell-bound antibodies were cross-linked for 1 min by additionto characterize the binding of Vav by CD19. Unstimu-
of avidin. The cells were lysed and CD19 was immunoprecipitatedlated murine splenic B lymphocytes, lymphocytes that
from cell lysates. The immunoprecipitated proteins were resolvedhad been activated by ligating either CD19 or mIg alone,
by SDS-PAGE; transferred to nitrocellulose; and immunoblotted with
and lymphocytes that had been activated by cross-link- monoclonal antibody to Vav, followed by enhanced chemilumines-
ing CD19 to mIg were compared for the extent to which cence (ECL) with 125I-labeled 4G10; and, after stripping, immunoblot-
CD19 had become tyrosine phosphorylated and for the ted with rabbit antibody to the cytoplasmic domain of mouse CD19
followed by ECL. The relative amounts of tyrosine phosphorylatedamount of Vav that was associated with CD19. In unstim-
CD19, total recovered CD19, and Vav were quantitated using aulated B lymphocytes, there was no detectable tyrosine
Molecular Dynamics densitometer. The signals obtained by scan-phosphorylation of CD19, and a relatively small amount
ning the control immunoprecipitate were subtracted, and the ratiosof Vav coimmunoprecipitated with CD19 (Figure 1). Li-
of Vav to total CD19 and of tyrosine phosphorylated CD19 to total
gating CD19 alone slightly augmented both measure- CD19 were calculated.
ments, as did ligating mIg alone. However, the coligation
of CD19 with mIg was found to have a synergistic effect,
increasing both the tyrosine phosphorylation of CD19 cytoplasmic domain of human CD19 (Tedder and Isaacs,
1989) were incubated with replicate samples of lysatesand the association with Vav by approximately 10- to
20-fold when these measurements were corrected for of Daudi human B lymphoblastoid cells. The agarose
beads were washed, and bound proteins were eluted,recovery of CD19. The diminished recovery of CD19 in
the detergent lysates of cells on which CD19 and mIg resolved by sodium dodecyl sulfate (SDS)±polyacryla-
mide gel electrophoresis (PAGE), and immunoblottedhad been coligated was caused by tight association
with detergent-insoluble cytoskeleton, and the high mo- with antibody to Vav. Only the peptide containing Y*391
bound Vav (Figure 2A), and only the phosphorylatedlecular form of phosphorylated CD19 was caused by
ubiquitination of the receptor (L. M. O. and D. T. F., form of this peptide adsorbed Vav from lysates of Daudi
and Ramos human B lymphoblastoid cells and murineunpublished data).
We determined which of the nine potential phospho- A20 cells (Figure 2B). These findings are consistent with
earlier work predicting the specificity of the SH2 domaintyrosines (Y*) of the cytoplasmic domain of CD19 binds
Vav. Streptavidin-agarose beads that had been coated of Vav (Songyang et al., 1994).
To determine whether tyrosine-391 mediated the bind-with each of nine biotinylated 11-mer peptides con-
taining Y* and flanking sequences corresponding to the ing of Vav to CD19 in vivo, Daudi B lymphoblastoid cells
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al., 1993), and the Y391F receptor, which had the addi-
tional modification of phenylalanine substituted for tyro-
sine-391 in the cytoplasmic domain (Li et al., 1997).
The transfectants were untreated or were activated by
cross-linking mIgM to induce the tyrosine phosphoryla-
tion of the chimeric receptors. These receptors and any
associated proteins were immunoprecipitated from ly-
sates with antibody to CD4, resolved by SDS-PAGE,
and revealed by sequential immunoblotting with anti-
bodies to Vav and the cytoplasmic domain of CD19,
respectively. A small amount of Vav coprecipitated with
the DEC and Y391F receptors from unstimulated cells;
an interaction of Vav with chimeric CD4-CD19 that was
independent of tyrosine-391 was also observed when
Vav was primarily immunoprecipitated (Figure 2C). Li-
gating mIgM increased the amount of Vav coprecipitat-
ing with the DEC receptor, but not that with the Y391F
receptor. Thus, the inducible interaction of CD19 with
Vav requires tyrosine-391.
CD19, Vav, and the Maintenance
of Elevated [Ca21]i
The role of Vav in the elevation of [Ca21]i induced by
either mIg or CD19 was examined in indo-1±loaded B
cells from normal mice and from mice in which Vav had
been interrupted by homologous recombination (Turner
et al., 1997). The delayed and modest increase in [Ca21]i
caused by ligating large numbers of CD19 alone on wild-
type Blymphocytes was absent in Vav2/2 B lymphocytes
(Figure 3A). In contrast, and as previously reported (Tar-
akhovsky et al., 1995; Zhang et al., 1995), cross-linking
mIg induced comparable increases in [Ca21]i in Vav1/1
and Vav2/2 B lymphocytes (Figure 3B). Coligating sub-
optimal numbers of CD19 and mIg led to a synergistic
initial increase in [Ca21]i that did not require Vav and aFigure 2. Interaction of Vav with Y*391 of CD19
sustained Ca21 response that was dependent on Vav
(A) Streptavidin±agarose beads coated with 11-mer biotinylated (Figures 3C and 3D). Therefore, Vav contributes to the
phosphotyrosyl peptides corresponding to sequences in the cyto-
regulation of [Ca21]i by CD19, especially the synergistic,plasmic domain of human CD19: PQNQY*(330)GNVLSL, TAPSY*
long-term ($10 min) elevation of [Ca21]i.(360)GNPSSD, EGEGY*(391)EEPDSE, DSEFY*(403)ENDSNL, DGSGY*
(421)ENPEDE, NAESY*(443)ENEDEL, GSQSY*(482)EDMRGI, RGILY*
(490)AAPQLR, and DADSY*(513)ENMDNP, were incubated with ly-
CD19 Activates PIP5K via Vavsates of Daudi B lymphoblastoid cells and adsorbed proteins were
Taken together, the requirement for Vav to maintain ele-eluted, resolved by SDS-PAGE, transferred to nitrocellulose, and
immunoblotted with antibody to Vav, followed by ECL. For compari- vated [Ca21]i, the requirement for the continued genera-
son, a whole-cell lysate and a CD19 immunoprecipitate were immu- tion I(1,4,5)P3 to sustain long-term Ca21 responses, the
noblotted with anti-Vav. rapid depletion of PI(4,5)P2 by PLC in other systems,
(B) Streptavidin±agarose beads coated with the phosphorylated and and the ability of two downstream targets of Vav, Rho
nonphosphorylated 11-mer peptides containing tyrosine-391 were
and Rac, to interact with PIP5K suggested that an im-incubated with lysates of Daudi, Ramos, and A20 cells. Bound pro-
portant function of the CD19±Vav complex may be toteins were eluted, resolved by SDS-PAGE, and immunoblotted with
antibody to Vav. induce the synthesis of PI(4,5)P2. To determine whether
(C) Replicate samples of Daudi B lymphoblastoid cells expressing the cross-linking of CD19 to mIg costimulates PIP5K,
the DEC (8 3 107 cells) or Y391F (4 3 107 cells) CD4/CD19 chimeric splenic B lymphocytes were activated by coligating a
receptors were held in buffer or stimulated for 1 min with F(ab9)2 suboptimal number of mIg with increasing amounts of
goat antibody to IgM. The chimeric receptors were immunoprecipi-
CD19, and, at the same time, permeabilizing the cellstated from cell lysates by incubation with antibody to CD4; Vav was
with streptolysin O (SLO) to permit the introduction ofdirectly immunoprecipitated with anti-Vav from a lysate of 2 3 107
stimulated cells expressing Y391F. The immunoprecipitated pro- [g32P]ATP. Lipids were extracted and separated, and the
teins were resolved by SDS-PAGE, transferred to nitrocellulose, and incorporation of [32P]PO4 into PIP2 determined. mIg alone
immunoblotted with antibody to Vav, and, after stripping, with rabbit induced a modest increment in PIP2 synthesis. Coli-
antibody to the cytoplasmic domain of CD19, followed by ECL. gating CD19 to mIg increased the synthesis of PIP2
in a synergistic and dose-related manner (Figure 4A).
Cross-linking CD19 alone also caused dose-dependentwere stably transfected with two chimeric CD4/CD19
receptors: DEC, in which the extracellular domain of synthesis of PIP2, which was lesser in magnitude (Fig-
ure 4A).CD19 was substituted with that of CD4 (Matsumoto et
Immunity
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Figure 3. Changes in [Ca21]i in B Cells from
Vav1/1 and Vav2/2 Mice Stimulated by CD19
or mIgAlone or by Cross-linking CD19 to Sub-
optimal mIg
Splenocytes from Vav1/1 mice (open sym-
bols) and Vav2/2 mice (closed symbols) were
stained with phycoerythrin-conjugated anti-
body to CD43, loaded with indo-1, and prein-
cubated with (A) biotinylated F(ab9)2 antibody
to CD19 at 10 mg/ml (squares) and 1 mg/ml
(circles); (B) biotinylated Fab antibody to k at
10 mg/ml (squares) and 0.1 mg/ml (circles); (C
and D) biotinylated Fab antibody to k at 0.1
mg/ml in the presence of biotinylated F(ab9)2
antibody to CD19 at 1 mg/ml (circles), or bio-
tinylated Fab isotype control antibody at 0.1
mg/ml together with biotinylated F(ab9)2 iso-
type control antibodyat 1 mg/ml (closed trian-
gles). After 20 sec, avidin was added, and the
analysis was continued for (A±C) 5 min or (D)
10 min, gating on CD432 cells. Changes in
[Ca21]i are indicated by changes in the ratio
of the fluorescence at 400±410 nm (FL1) and
at 460±480 nm (FL2). Data are representative
of three independent experiments.
To confirm that the PIP2 induced by CD19 was from PI(4,5)P2 were recovered as [32P]PI(4)P, whereas
82% of the hydrolyzed [3H]PI(4,5)P2 was recovered asPI(4,5)P2, the PIP2 was deacylated and analyzed by
anion-exchange high-performance liquid chromatogra- [3H]PI(4)P. In two additional experiments, the recoveries
of CD19-induced [32P]PI(4,5)P2 as [32P]PI(4)P followingphy. Approximately 90% of the counts were in the
GroPI(4,5)P2 peak, the deacylated product that is de- treatment with the 5-phosphatase were 28% and 29%,
while the correspondingrecoveries for [3H]PI(4,5)P2 wererived from PI(4,5)P2. The deacylated product of PI(3,4)P2,
GroPI(3,4)P2, was not present (data not shown). 94% and 88%. The capacity of the synaptojanin (5)Ptase
tocause a preferential loss of label from the [32P]PI(4,5)P2We determined whether Vav participated in this stimu-
lation of PI(4,5)P2 synthesis by activating splenic B lym- induced by CD19 indicates that this phospholipid had
beenphosphorylated at position5 through theactivationphocytes from Vav1/1 and Vav2/2 mice. In wild-type
cells, ligating large numbers of mIg or CD19 induced of PIP5K. The residual 32P in the PI(4)P may indicate
either that a portion of the substrate of the PIP5K acti-the synthesis of PI(4,5)P2, as did the synergistic interac-
tion of suboptimal numbers of mIg and CD19 (Figure vated by CD19 had already been endogenously labeled
by a constitutively active PI4K (Figures 4C, 5A, and 6A),4B). The synergistic- and mIg-mediated reactions were
reduced by approximately 50% in the Vav2/2 B lympho- or that CD19 also activates a PI(5)P4K.
CD19 resides in a complex with CD21 and CD81, andcytes, and CD19 alone was inactive in these cells (Figure
4B). A stringent requirement of CD19 for Vav was con- the latter has been shown to amplify the Ca21 response
when coligated with mIg (Matsumoto et al., 1993). Thefirmed when the dose-dependent increase in PI(4,5)P2
induced by CD19 in wild-type B lymphocytes was found association of CD81 with CD19 requires the extracellular
domain of CD19 (Bradbury et al., 1993; Matsumoto etto be absent in Vav2/2 cells (Figure 4C).
Although Rho and Rac have been shown to interact al., 1993). We determined whether the effects of CD19
on the activation of PIP5K and maintenance of elevatedwith PIP5K, a recent study has identified a PI(5)P4K that
phosphorylates PI5P to generate PI(4,5)P2 (Rameh et al., [Ca21]i required CD81 by examining these reactions in
the Daudi B cell transfectants expressing the CD4±CD191997). To confirm that CD19 activates a PI(4)P5K rather
than a PI(5)P4K, the [32P]PI(4,5)P2 induced by CD19 was chimeras. The transfectants were activated by coligat-
ing a suboptimal number of mIg with incremental num-treated with the phosphatase synaptojanin, which pref-
erentially dephosphorylates position 5 of the inositol bers of DEC and Y391F, respectively, to which anti-CD4
had been bound. Synthesis of PI(4,5)P2 was measuredring of PI(4,5)P2 (Woscholski et al., 1995). [3H]PI(4,5)P2
was added to the reaction as an independent measure by introducing [g32P]ATP into the SLO-permeabilized
cells and determining the incorporation of [32P]PO4 intoof PI(4,5)P2 hydrolysis and recovery of PIP, since the
radiolabel will not be affected by the dephosphorylation. PI(4,5)P2. DEC caused a dose-related synergistic activa-
tion of PIP5K when cross-linked to mIg (Figure 5A); itWhen the [32P]PI(4,5)P2 induced by CD19 was dephos-
phorylated by synaptojanin, only 17% of the counts lost did not augment the synthesis of PI(4,5)P2 when ligated
Interaction of CD19 with Vav in B Lymphocytes
639
Figure 4. Synthesis of [32P]PI(4,5)P2 in B Cells
from Vav1/1 and Vav2/2 Mice
(A) Splenic B cells were preincubated with
incremental concentrations of biotinylated
Fab antibody to CD19 in the absence or pres-
ence of a suboptimal concentration of biotin-
ylated Fab antibody to k (0.04 mg/ml). In this
experiment and those depicted in (B) and (C),
the cell-bound antibodies were cross-linked
by avidin for 1 min in buffer containing SLO
and [g32P]ATP, after which the synthesis of
[32P]PI4P (in B and C) and [32P]PI(4,5)P2 was
measured.
(B) B cells from Vav1/1 mice (92% B2201) and
Vav2/2 mice (91% B2201) were preincubated
with the following biotinylated antibody frag-
ments: control Fab (10 mg/ml); Fab anti-k
(1 mg/ml and 0.04 mg/ml); Fab anti-CD19 (10
mg/ml and 1 mg/ml); and Fab anti-k (0.04 mg/
ml) in the presence Fab anti-CD19 (1 mg/ml).
(C) B cells from Vav1/1 mice (89% B2201) and
Vav2/2 mice (85% B2201) were preincubated
with incremental concentrations of biotinyl-
ated Fab monoclonal antibody to CD19 or
biotinylated control Fab antibody. Data are
representative of three independent experi-
ments.
alone. Endogenous CD19 alone also does not activate 3C and 3D). The Y391F chimera, which does not associ-
ate with CD81, lacked this response in the Daudi B cellsPIP5K in these cells (data not shown). Y391F was inac-
(Figure 5B).tive in the synergistic response with mIg, even though
We wished to determine whether a guanine nucleo-it was expressed at 5-fold higher numbers per cell than
tide±binding protein mediated the activation of PIP5Kthe DEC receptor. Coligating DEC or Y391F to mIg did
by CD19 because of the involvement of the GEF, Vav,not induce synthesis of PI4P.
in this reaction. The transformed murine B lymphomaThe two chimeric receptors were also assessed for
line, Bal17, was stimulated by cross-linking CD19 andtheir ability to costimulate increases in [Ca21]i. By ad-
permeabilized with SLO in the presence of [g32P]ATPjusting the concentrations of anti-CD4, equivalent num-
and increasing concentrations of GDPbS. Measurementbers of DEC and Y391F were ligated alone, or a subopti-
of the synthesis of PI(4,5)P2 demonstrated that GDPbSmal number of mIg were ligated alone with anti-Ig, or
inhibited the activation of PIP5K in a dose-related man-
mIg and CD4-CD19 were cross-linked together on
ner (Figure 6A). To assess whether Rho was the GDPbS-
transfectants that had been loaded with indo-1. A syner-
inhibitable GTPase, we introduced into Bal17 cells the
gistic increase in [Ca21]i occurred when DEC was cross- Clostridium botulinum C3 exoenzyme, which specifi-
linked to mIg, but Y391F lacked this function (Figure 5B). cally ADP ribosylates and inactivates Rho (Aktories and
Similar findings were obtained with additional clones of Hall, 1989). Greater than 95% ADP ribosylation of Rho
these transfectants. Therefore, CD81 is not required for (Figure 6B) had no effect on the capacity of CD19 or
either the activation by CD19 of PIP5K or a sustained on that of the positive control, GTPgS, to induce the
increase in [Ca21]i, and the Vav dependence of these synthesis of PI(4,5)P2 (Figure 6C). These observations
reactions is confirmed. However, CD81 may have con- are consistent with a GTP-dependent, but Rho-indepen-
tributed to the initial synergistic increase in [Ca21]i in- dent, activation of PIP5K by CD19 and Vav, and indicate
that another GTPase may be relevant, such as Rac,duced by intact CD19 in Vav-deficient B cells (Figures
Immunity
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Figure 6. Effects of GDPbS and C. botulinum C3 Transferase on
Synthesis of [32P]PI(4,5)P2 in B Cells Stimulated by CD19
(A) Bal17 cells were preincubated with 5 mg/ml of the biotinylated
Figure 5. Synthesis of [32P]PI(4,5)P2 and Changes in [Ca21]i in Daudi Fab fragments of antibody to CD19 or the nonspecific control anti-
B Lymphoblastoid Cells Costimulated by mIg and the CD4/CD19 body. The cell-bound antibodies were cross-linked for 1 min by
Chimeras, DEC, and Y391F addition of avidin (20 mg/ml) in buffer containing SLO and [g32P]ATP
alone or with the indicated concentrations of GDPbS, after which(A) The transfectants were preincubated with incremental concen-
the synthesis of [32P]PI4P and [32P]PI(4,5)P2 was measured.trations of the Fab fragment of mouse monoclonal anti-CD4 in the
(B) Bal17 cells were electroporated in the absence (-) or presenceabsence (open symbols) or presence (closed symbols) of a subopti-
(C3) of 100 mg/ml C3 transferase and subsequently cultured for 5mal concentration of Fab mouse monoclonal anti-human IgM (0.01
hr. An aliquot of the cells was washed, lysed, and incubated withmg/ml). Because of higher expression on the transfectants of Y391F
C3 transferase and 32P-NAD. The proteins in the lysate were sepa-than of DEC, the former bound 5-fold more anti-CD4 than did the
rated by SDS-PAGE and subjected to autoradiography to determinelatter, as determined by flow cytometry. The cell-bound antibodies
the extent of in vivo ADP ribosylation of Rho.were cross-linked by addition of F(ab9)2 goat antibody to mouse
(C) The remaining mock or C3 transferase±treated cells were prein-IgG. After 1 min, buffer containing SLO and [g32P]ATP was added
cubated with 5 mg/ml of the biotinylated Fab fragments of antibodyand the incubation was continued for 1 min,after which the synthesis
to CD19 or with control antibody. The cell-bound antibodies wereof [32P]PI4P and [32P]PI(4,5)P2 was determined.
cross-linked for 1 min by addition of avidin (20 mg/ml) in buffer(B) Daudi transfectants were loaded with indo-1 and preincubated
containing SLO and [g32P]ATP. For stimulation with GTPgS, bufferwith concentrations of biotinylated Fab anti-CD4 that yielded equiv-
containing SLO and [g32P]ATP alone or with 100 mM GTPgS wasalent binding to the transfectants (open diamonds), a single concen-
added to cells. After 1 min, the reactions were stopped and thetration of biotinylated Fab anti-IgM that was below the threshold
synthesis of [32P]PI(4,5)P2 was measured. Data are representativefor raising [Ca21]i (open squares), or both (closed circles). The cells
of three independent experiments.were washed; avidin was added to cross-link the cell-bound anti-
bodies; and indo-1 fluorescence was measured. Shown is the ratio
of the fluorescence at 400±410 nm (FL1) and at 460±480 nm (FL2).
Data are representative of three independent experiments. fragments of antibodies to k and CD19 alone or together,
followed by immunoprecipitation of JNK and, for com-
parison, ERK2, from cell lysates. Using in vitro kinase
which has been found to activate PIP5K in another he- assays, we measured the activities of JNK by phosphor-
matopoietic cell type, the platelet (Hartwig et al., 1995). ylation of a GST-c-Jun1±194 fusion protein, and of ERK2
by phosphorylation of GST-Elk1C fusion protein. Ligat-
ing mIg or CD19 alone did not substantially activateCostimulation of JNK by mIg and CD19
Requires Vav either MAP kinase (Figure 7A) in either type of B lympho-
cyte; in other experiments, higher amounts of ligatedThe finding that CD19 recruits the function of Vav, cou-
pled with the known ability of Vav to activate JNK mIg induced modest activation of ERK2 (data not shown).
Coligating mIg and CD19 on wild-type B lymphocytesthrough Rac and Cdc42 (Crespo et al., 1996), offered a
possible mechanism for the costimulation by CD19 of caused a synergistic activation of both JNK and ERK2.
In the absence of Vav, costimulation of ERK2 was main-this MAP kinase. B lymphocytes from Vav1/1 and Vav2/2
mice were stimulated by cross-linking cell-bound Fab tained, but activation of JNK was diminished by up to
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Figure 7. Activation of JNK and ERK by Coligated CD19 and mIg in B Cells from Vav1/1 and Vav2/2 Mice
(A) B cells from Vav1/1 mice (solid bars) and Vav2/2 mice (hatched bars) were incubated with biotinylated Fab fragments of isotype-matched,
nonspecific control antibody (10 mg/ml), or with Fab fragments of monoclonal antibody to CD19 (5 mg/ml) and k (5 mg/ml) alone or together.
Cells were washed and stimulated for 10 min at 378C by addition of avidin (20 mg/ml). Stimulation was stopped by addition of lysis buffer,
and replicate samples of the lysates were subjected to immunoprecipitation with antibodies to ERK2 or JNK1. The immunoprecipitates were
assayed for ERK and JNK activities by phosphorylation, in the presence of [g32P]ATP, of the fusion proteins GST-Elk1C and GST-c-Jun1±194,
respectively (Tooze et al., 1997). Shown are the autoradiographs of the GST fusion proteins and their relative incorporation of 32P.
(B) (Left) B cells from Vav1/1 mice (closed squares) and Vav2/2 mice (open squares) were incubated with buffer alone or containing 500 ng/
ml PMA for timed intervals, after which cells were lysed. The activity of JNK in the lysates was assayed and expressed relative to that of cells
treated with buffer only. (Right) B cells from Vav1/1 mice (closed squares) and Vav2/2 mice (open squares) were incubated with biotinylated
Fab fragments of antibodies to CD19 and k together at doses (0.5 mg/ml) that alone were nonstimulatory, or with Fab fragments of an isotype-
matched, nonspecific control antibody (1 mg/ml). The cells were washed and stimulated by addition of avidin (20 mg/ml) and incubation
continued for timed intervals, after which the cells were lysed. The activity of JNK in the lysates was assayed and expressed relative to that
of cells treated with control antibody. Data are representative of three independent experiments.
80% (Figure 7A). Analysis of the time course of JNK When tyrosine phosphorylated, it recruits cytoplasmic
effector proteins containing SH2 domains that amplifyactivation by mIg/CD19 coligation demonstrated that
over the entire 15 min period of observation, the costim- signaling by the mIg complex, the first example of which
was the binding by phosphorylated tyrosines-482 andulation of JNK was diminished in B lymphocytes from
Vav2/2 mice, whereas that by phorbol myristate acetate -513 of PI3K (Tuveson et al., 1993), which has been
shown to contribute to mIg-induced increase in [Ca21]i(PMA) was independent of Vav (Figure 7B). Hence, the
activation of JNK by mIg and CD19 is mediated, in part, (Buhl et al., 1997). This general concept is extended in
the present study by finding that tyrosine-391 of CD19by Vav, but activation of ERK2, which may be mediated
by another GTPase, Ras, is not. The residual activation binds Vav to activate PIP5K and elevate [Ca21]i and
to costimulate JNK. Thus, the phosphotyrosine-basedof JNK in Vav2/2 B lymphocytes may be caused by Ras-
dependent activation of Rac (Coso et al., 1995; Minden adaptor function of CD19 augments the stimulation by
mIg of at least two lipid kinases and a protein kinase.et al., 1995).
The role of CD19 as a costimulator of mIg-induced
activation of the B lymphocyte requires its cross-linkingDiscussion
to mIg (Carter and Fearon, 1992). Because of the associ-
ation of CD19 with CD21, this process occurs physiolog-CD19 serves as a membrane-anchored adaptor protein
that enhances activation of the B lymphocyte by mIg. ically when antigen has been tagged with C3d. There
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are two possible explanations for this requirement: jux- long-term Ca21 response in B lymphocytes that have
been costimulated by mIg and CD19 (Figures 3C andtaposition of CD19, with its associated cytosolic pro-
teins, to mIg creates a more effective signaling complex, 3D). These findings may explain early studies that found
that GTPgS enhanced, and GDPbS suppressed, mIg-and the tyrosine phosphorylation of CD19, which medi-
ates the binding of these cytosolic proteins, is regulated induced generation of I(1,4,5)P3 (Gold et al., 1987; Har-
nett and Klaus, 1988).by mIg. Although CD19 can be phosphorylated when
either it or mIg is ligated alone, the present work shows We have not determined whether the increased avail-
ability of PI(4,5)P2 accounts entirely for the effect ofthat cross-linking CD19 to mIg causes a 10- to 20-fold
greater tyrosine phosphorylation of CD19 than when CD19 on [Ca21]i. For example, even in the absence of
Vav, coligating CD19 to mIg caused an initial, synergisticeither receptor was ligated alone (Figure 1). This is the
most proximal synergistic reaction of CD19 and mIg that increase in [Ca21]i (Figure 3) and diminished, but resid-
ual, synthesis of PI(4,5)P2, which may reflect compensa-has been observed. This synergistic phosphorylation
of CD19 is probably relevant to signaling since it was tion by Vav2 in the Vav2/2 cells (Schuebel et al., 1996).
However, all activities were lost with Y391F, the chimericaccompanied by a comparable increase in the binding
of Vav (Figure 1) and PI3K (data not shown). The mecha- CD4±CD19 fusion protein lacking the extracellular do-
main of CD19 and the site for interaction with Vav (Figurenism of this effect may involve the phosphorylation of
CD19 by protein kinases associated with the mIg com- 5). Since this domain mediates the interaction of CD19
with CD81, and CD81 alone has been shown also toplex, such as Lyn or Syk; by other kinases that are
activated by mIg, such as Btk; or by the more effective enhance synergistically the increase in [Ca21]i induced
by mIg (Matsumoto et al., 1993), the early increment inactivation of the Lyn or Fyn that is associated with CD19.
In any event, this finding indicates that synergistic [Ca21]i may be mediated by CD81. The recruitment of
this function of CD81 by CD19 would represent an extra-signaling by coligated CD19 and mIg occurs at an early
first step, and emphasizes that an essential characteris- cellular, rather than intracellular, ªadaptorº function for
the receptor. However, even the absence of any syner-tic of stimulatory antigen must be its physical associa-
tion with a ligand for the CD19±CD21 complex, either gistic increase in [Ca21]i with the Y391F mutant cannot
be taken as proof of a role only for Vav or Vav2 becausethrough attachment of C3d or possibly by its presence
on membranes bearing a ligand for this complex, such other cellular proteins may interact with this tyrosine,
as has been suggested by the requirement of tyrosine-as CD23. An earlier finding that coligating CD19 to mIgM
on Daudi B lymphoblastoid cells did not increase the 391 for ERK2 costimulation (Li et al., 1997), a response
that does not require Vav (Figure 6).tyrosine phosphorylation of CD19 (Li et al., 1997) may
reflect the more robust activation of kinases by mIgM in Vav has not been described previously as activating
PIP5K, although focal regulation of the level of PI(4,5)P2,this cell having a deficiency of the tyrosine phosphatase
SHP-1 (Delibrias et al., 1997). which interacts with actin-binding proteins (Janmey,
1994; Hartwig et al., 1995), could contribute to severalThe first signal-transducing function that was de-
scribed for CD19 was the elevation of [Ca21]i (Pezzutto of its effects on the organization of the cytoskeleton
(Khosravi-Far et al., 1994). Two GTPase targets of Vav,et al., 1987). This response, like tyrosine phosphoryla-
tion, can occur when CD19 or mIg is ligated alone, but Rho and Rac, interact with PIP5K. Although we obtained
evidence for the involvement of a guanine nucleotide±is most pronounced when CD19 and mIg are cross-
linked together (Carter et al., 1991). We established a binding protein by inhibiting CD19-mediated activation
of PIP5K with GDPbS (Figure 5), we did not identifycausal relationship between tyrosine phosphorylation
and the Ca21 response by finding that the enhanced the GTPase mediating PIP5K activation because ADP
ribosylation of Rho did not impair this reaction (Figurephosphorylation of CD19 was accompanied by in-
creased association with Vav (Figure 1); that phosphory- 5). These findings suggest, by exclusion of Rho, an
involvement of Rac, but this pathway leading from Vavlated tyrosine-391 bound Vav (Figure 2); and that the
absence of Vav (Figure 3), or mutation of tyrosine-391 to PIP5K remains to be defined.
CD19 has been found recently to costimulate ERK2,(Figure 5), impaired the CD19-dependent Ca21 response.
These studies have also provided a reasonable explana- JNK, and p38 (Tooze et al., 1997), and one report has
shown a requirement for tyrosine-391 in the activationtion for the contribution of Vav to the Ca21 response
mediated by CD19, which is the activation of PIP5K of ERK2 (Li et al., 1997). Although Vav had been de-
scribed as a GEF for Ras, which would have been con-leading to the synthesis of PI(4,5)P2 (Figures 4±6). The
rapid depletion of PI(4,5)P2 by PLC, which in other cellu- sistent with tyrosine-391 mediating the costimulation of
ERK2 by this pathway, subsequent studies have indi-lar systems occurs within seconds of receptor-mediated
stimulation (Stephens et al., 1993), would impair the cated a role for Vav in the activation of the Rho family
of GTPases rather than Ras (Bustelo et al., 1994). Con-continued generation of I(1,4,5)P3 unless stimulation was
also coupled to the activation of a biosynthetic pathway sistent with these more recent findings, we found that
Vav contributed to activation of JNK but not ERK2 (Fig-for PI(4,5)P2. mIg is coupled to the activation of PIP5K,
but only when high concentrations of ligand are used ure 6). Therefore, tyrosine-391, whether phosphorylated
or not, may interact with another cytosolic protein in(Figure 4B). The costimulatory effect on the generation
of I(1,4,5)P3 occurring when CD19 is cross-linked to sub- addition to Vav, to mediate this Ras-dependent MAP
kinase pathway.optimal amounts of mIg would therefore require another
means by which the synthesis of PI(4,5)P2 could be in- The CD19±CD21 complex links innate immune recog-
nition of antigen to the acquired immune response, en-creased above basal levels. The interaction of CD19
with Vav meets this requirement, contributing to the abling the B lymphocyte to bias its response to antigens
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pepstatin A, chymostatin (6 mg/ml), aprotinin (1 mg/ml), and 4-(2-of microbial origin that have activated the complement
aminoethyl)-benzenesuflonyl fluoride (1 mg/ml) (Calbiochem). Ly-system. Both receptors are required for the normal de-
sates were precleared by incubation with a nonspecific rat IgG2avelopment of the germinal center in which occur the
and rabbit anti-rat IgG followed by protein A. CD19 was immunopre-
essential B lymphocyte responses of isotype switching, cipitated from cell lysates by incubation with 1D3 rat antibody to
somatic mutation of mIg, selection, and the generation CD19 and rabbit anti-rat IgG followed by protein A trisacryl.
of memory B lymphocytes. The present finding that
CD19 recruits the product of a protooncogene, Vav, to Biosynthetic Labeling and Quantitation of Phospholipids
Cells in Hanks' balanced salt solution without Mg21or Ca21 wereregulate lipid and protein kinases that serve two distinct
preincubated with appropriate Fab antibody fragment for 15 min atsignaling pathways is consistent with the importance of
room temperature, washed, and activated by addition of avidin orthese biological functions of the CD19-CD21 complex.
F(ab9)2 goat antimouse immunoglobulin at 20 mg/ml in intracellular
buffer (Alexander et al., 1989) at 378C. Cells were permeabilized at
Experimental Procedures 378C by adding 50 ml of SLO (0.8 IU/ml) containing 10 mCi [32P]gATP,
giving a final concentration of 100 mM ATP. In some experiments
Reagents cells were stimulated and permeabilized at the same time. After 1
The following reagents were purchased: Phosphatidylserine, PI4P, min of permeabilization, the reaction was quenched with 600 ml of
PI(4,5)P2, GTPgS, GDPbS, avidin, and antibody to Thy1.2 (Sigma), chloroform/methanol/HCl (1:2:1) containing 10 mg of phosphatidyl-
silicia gel-60 thin layer chromatography plates (Whatman), SLO (Mu- serine. Two hundred microliters of chloroform and 200 ml of 2.4 M
rex Biotech), indo-1-AM (Molecular Probes), biotinylated CD19 pep- HCl were added and the lower phase was washed with 800 ml of
tides (Quality Controlled Biochemicals), streptavidin agarose and methanol:1 M HCl (1:1). The lipid extract was dried under nitrogen
protein A±trisacyl (Pierce), glutathione sepharose and GammaBind and resuspended in chloroform for spotting on potassium oxalate±
Plus Sepharose (Pharmacia Biotech), [g32P]ATP, and [32P]NAD impregnated thin-layer chromatography (TLC) plates. The TLC
(Amersham). The construct for C. botulinum C3 exoenzyme GST plates were developed in chloroform/methanol/acetone/acetic acid/
fusion protein was a gift from Alan Hall and the constructs for GST-c- H20 (80:30:26:24:14), and the [32P] incorporated into PIP; PIP2 was
Jun1±194 and GST-Elk1C fusion proteins were provided by Doreen quantitated using a Packard-Bell InstantImager.
Cantrell and Richard Treisman, respectively. Active C3 transferase
was purified by removal of GST by thrombin cleavage. Recombinant Preparation of PI(4,5)P2 Substrate and 5-phosphatase Assay
synaptojanin was kindly supplied by R. Woscholski. CD19-induced, 32P-labeled PI(4,5)P2 was recovered from Bal17 cells
by lipid extraction and TLC. [3H]PI(4,5)P2 (0.05 mCi) and sufficient
Antibodies unlabeled PIP2 were added to each to yield 36 mg of PI(4,5)P2 per
The following antibodies were used: 1D3 rat IgG2a antibody to extract, dried under nitrogen, and sonicated in 120 ml 0.5% CHAPS,
mouse CD19 (Krop et al., 1996), DA4.4 mouse anti-human IgM (Car- 0.2 M Tris (pH 7.4). Synaptojanin was incubated with 40 ml of
ter et al., 1991), rabbit antibodies to the cytoplasmic domains of [3H]PI(4,5)P2/[32P]PI(4,5)P2 in 120 ml containing 5 mM MgCl2, 0.5 mM
human CD19 (Tuveson et al., 1993) and mouse CD19 (Krop et al., EGTA, 70 mM Tris (pH 7.4), and 0.17% CHAPS for 2 hr at 378C. The
1996), LO-MK-1 rat IgG2a antibody to mouse k and IR 418 rat IgG2a phospholipids were separated by TLC, the spots corresponding to
myeloma (Zymed), F(ab9)2 goat antibodies to human IgM (Tago) and PIP and PIP2 identified by iodine vapor, scraped, and counted by
mouse IgG (Jackson), monoclonal antibody to Vav, rabbit polyclonal liquid scintillation.
antibody to Vav, 4G10 anti-phophosotyrosine antibody (Upstate
Biotechnology), monoclonal antibody to CD4 (Caltag), G151±333.8 ADP Ribosylation with C3 Exoenzyme
mouse monoclonal antibody to mouse JNK1, and phycoerythrin- Replicate 0.8 ml aliquots of Bal17 cells at 2 3 107/ml in phosphate-
conjugated S7 rat monoclonal antibody to mouse CD43 (Phar- buffered saline/10 mM glucose/1 mM MgCl2 in the presence or ab-
mingen). Fab fragments were produced by papain digestion and sence of 100 mg/ml C3 exotoxin were subjected to a discharge
were biotinylated with ImmunoPure Sulfo-NHS-Biotin (Pierce). Se- of 0.4 V from a 25 mF capacitor using the gene pulser (Bio-Rad
rum 122 rabbit antiserum to ERK2 was provided by Christopher Laboratories). After 10 min at 48C, cells were resuspended at 1±2 3
J. Marshall. 105/ml in culture media and allowed recover for 5 hr at 378C before
stimulation or ADP ribosylation of lysates (Yamamoto et al., 1993).
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Daudi cells expressing the DEC and Y391F CD4-CD19 chimeras Acknowledgments
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